SERNOVA BIOTHERAPEUTICS INC (PSH0.DE) Forecast, Price Target & Analyst Ratings

FRA:PSH0 • CA81752F1062

Current stock price

0.1 EUR
-0.01 (-7.41%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SERNOVA BIOTHERAPEUTICS INC (PSH0.DE).

Forecast Snapshot

Consensus Price Target

Price Target
€2.27
+ 2,167.36% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
N/A
Period
Q1 / 2026
EPS Estimate
-CA$0.01
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
80.00%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
€2.27
Upside
+ 2,167.36%
From current price of €0.10 to mean target of €2.27, Based on 7 analyst forecasts
Low
€0.31
Median
€2.27
High
€4.34

Price Target Revisions

1 Month
-1.98%
3 Months
11.63%

Price Target Summary

7 Wall Street analysts provided a forecast for the next 12 months for PSH0.DE. The average price target is 2.27 EUR. This implies a price increase of 2167.36% is expected in the next year compared to the current price of 0.1.
The average price target has been revised upward by 11.63% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

PSH0 Current Analyst RatingPSH0 Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4

Analyst Ratings History

PSH0 Historical Analyst RatingsPSH0 Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8

Analyst Ratings Consensus

ChartMill Buy Consensus
80.00%
PSH0.DE was analyzed by 7 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about PSH0.DE.
In the previous month the buy percentage consensus was at a similar level.
PSH0.DE was analyzed by 7 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Next Earnings Forecast Details

Next Earnings Details

Release Date
N/A
Period
Q1 / 2026
EPS Estimate
-CA$0.01
Revenue Estimate
Revenue Q2Q
N/A
EPS Q2Q
66.67%
Number of Analysts
2

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
N/A

Next Earnings Summary

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
PSH0.DE revenue by date.PSH0.DE revenue by date.
N/AN/AN/A
954.68%		N/A
3,979.35%		N/A
-6.52%		N/A
140.87%		N/A
68.95%		N/A
35.68%		N/A
22.11%
EBITDA
YoY % growth
PSH0.DE ebitda by date.PSH0.DE ebitda by date.
N/A-2.494M
-17.59%		-2.604M
-4.39%		-3.642M
-39.88%		-3.947M
-8.37%		-5.035M
-27.57%		-6.669M
-32.47%		-24.314M
-264.56%		-40.056M
-64.75%		-31.123M
22.30%		-14.68M
52.83%		N/A
29.72%		N/A
25.41%		N/A
40.20%		N/A
741.57%		N/A
352.81%		N/A
85.45%		N/A
56.69%		N/A
35.36%
EBIT
YoY % growth
PSH0.DE ebit by date.PSH0.DE ebit by date.
N/A-2.502M
4.74%		-2.643M
-5.67%		-3.706M
-40.21%		-4.008M
-8.14%		-5.26M
-31.23%		-6.937M
-31.88%		-24.754M
-256.86%		-40.502M
-63.62%		-31.664M
21.82%		-15.023M
52.55%		N/A
-191.78%		N/A
286.41%		N/A
470.33%		N/AN/AN/AN/AN/A
Operating Margin
PSH0.DE operating margin by date.PSH0.DE operating margin by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
EPS
YoY % growth
PSH0.DE eps by date.PSH0.DE eps by date.
N/AN/AN/AN/AN/AN/A
50.00%		N/A
-50.00%		-0.09
-494.06%		-0.13
-44.44%		-0.09
30.77%		N/A
4.61%		N/A
58.82%		N/A
28.57%		N/A
800.00%		N/A
-32.63%		N/A
170.91%		N/A
50.78%		N/A
32.64%		N/A
22.32%

All data in CAD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26
EPS
Q2Q % growth		-0.01
66.67%		-0.01
-1.00%
Revenue
Q2Q % growth
EBITDA
Q2Q % growth		N/AN/A
EBIT
Q2Q % growth		N/AN/A

All data in CAD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

PSH0.DE Yearly Revenue VS EstimatesPSH0.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
PSH0.DE Yearly EPS VS EstimatesPSH0.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 0.2 0.4 0.6

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
19.80%
EPS Next 5 Year
27.15%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
23.38%
EBIT Next 5 Year
40.83%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

SERNOVA BIOTHERAPEUTICS INC / PSH0.DE Forecast FAQ

What do analysts expect the price target to be for SERNOVA BIOTHERAPEUTICS INC (PSH0.DE)?

7 analysts have analysed PSH0.DE and the average price target is 2.27 EUR. This implies a price increase of 2167.36% is expected in the next year compared to the current price of 0.1.

What are the consensus estimates for SERNOVA BIOTHERAPEUTICS INC (PSH0.DE) next earnings?

The consensus EPS estimate for the next earnings of SERNOVA BIOTHERAPEUTICS INC (PSH0.DE) is -0.01 EUR and the consensus revenue estimate is 0 EUR.

What is the consensus rating for SERNOVA BIOTHERAPEUTICS INC (PSH0.DE) stock?

The consensus rating for SERNOVA BIOTHERAPEUTICS INC (PSH0.DE) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.